menu search

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Optinose Reports First Quarter 2023 Financial Results and Operational Updates
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 11, 2023 […] The post Optinose Reports First Quarter 2023 Financial Results and Operational Updates appeared first on ForexTV... Read More
Posted: May 11 2023, 11:00
Author Name: forextv
Views: 081753

Search within

Pages Search Results: